Free Trial

Q3 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst

Eton Pharmaceuticals logo with Medical background

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities research analysts at B. Riley boosted their Q3 2025 earnings estimates for Eton Pharmaceuticals in a research report issued on Wednesday, July 16th. B. Riley analyst M. El-Saadi now anticipates that the company will post earnings per share of $0.16 for the quarter, up from their previous estimate of $0.15. B. Riley has a "Buy" rating and a $26.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' Q4 2025 earnings at $0.42 EPS, FY2026 earnings at $1.06 EPS and FY2027 earnings at $1.74 EPS.

ETON has been the topic of a number of other reports. Craig Hallum raised their price target on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price (up previously from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th.

Get Our Latest Stock Analysis on ETON

Eton Pharmaceuticals Price Performance

NASDAQ ETON traded down $0.62 during trading hours on Friday, reaching $14.40. The company's stock had a trading volume of 335,466 shares, compared to its average volume of 276,949. The stock has a market cap of $386.21 million, a PE ratio of -80.00 and a beta of 1.18. Eton Pharmaceuticals has a fifty-two week low of $3.25 and a fifty-two week high of $21.48. The company's 50-day moving average is $16.14 and its two-hundred day moving average is $15.33. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.43 and a current ratio of 1.97.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.02). The business had revenue of $17.28 million during the quarter, compared to analysts' expectations of $14.33 million. Eton Pharmaceuticals had a negative net margin of 9.49% and a negative return on equity of 3.15%.

Insiders Place Their Bets

In other news, insider David Krempa sold 16,977 shares of Eton Pharmaceuticals stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $14.92, for a total transaction of $253,296.84. Following the completion of the transaction, the insider directly owned 629,669 shares in the company, valued at approximately $9,394,661.48. The trade was a 2.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 34,000 shares of company stock valued at $504,318 in the last ninety days. 14.89% of the stock is owned by company insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Eton Pharmaceuticals by 18.3% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock valued at $141,000 after purchasing an additional 1,634 shares in the last quarter. XTX Topco Ltd boosted its position in shares of Eton Pharmaceuticals by 29.6% during the 4th quarter. XTX Topco Ltd now owns 14,655 shares of the company's stock valued at $195,000 after purchasing an additional 3,351 shares in the last quarter. AlphaQuest LLC bought a new stake in shares of Eton Pharmaceuticals during the 1st quarter valued at about $53,000. Tower Research Capital LLC TRC bought a new stake in shares of Eton Pharmaceuticals during the 4th quarter valued at about $86,000. Finally, Quantbot Technologies LP acquired a new position in Eton Pharmaceuticals during the 1st quarter worth approximately $101,000. 27.86% of the stock is owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

(Get Free Report)

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

Recommended Stories

Earnings History and Estimates for Eton Pharmaceuticals (NASDAQ:ETON)

Should You Invest $1,000 in Eton Pharmaceuticals Right Now?

Before you consider Eton Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.

While Eton Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines